Pharming Group (PHAR) Expected to Announce Quarterly Earnings on Thursday

Pharming Group (NASDAQ:PHAR) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 7:30 AM ET.

Pharming Group Price Performance

PHAR opened at $13.14 on Tuesday. The company has a fifty day simple moving average of $14.31 and a 200 day simple moving average of $11.89. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38. The firm has a market cap of $899.88 million, a price-to-earnings ratio of -101.04 and a beta of 0.03. Pharming Group has a twelve month low of $7.31 and a twelve month high of $17.08.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Zacks Research cut Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 30th. Weiss Ratings upgraded shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Pharming Group presently has an average rating of “Moderate Buy” and a consensus target price of $30.00.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.